Roche Holding AG / Anadys Pharmaceuticals, Inc.

Chronic Hepatitis C Virus Infection

67K US cases/yr

Disease Overview

Chronic HCV is a slowly progressive liver disease causing fibrosis, cirrhosis, hepatocellular carcinoma, and need for transplant. Genotype 1, the dominant US strain, was historically the hardest to treat. The 2011 industry inflection point was the move from interferon-based regimens to all-oral direct-acting antivirals (DAAs), reshaping deal economics across HCV portfolios.

Competitive Landscape

By Q4 2011, every large hepatology player was building a DAA toolkit. Vertex's Incivek (telaprevir) and Merck's Victrelis (boceprevir) protease inhibitors had launched mid-2011 atop the interferon/ribavirin standard. Gilead's $11B Pharmasset acquisition (November 2011) for PSI-7977 (later sofosbuvir/Sovaldi) was the defining transaction; BMS followed with $2.5B for Inhibitex (January 2012). Abbott was advancing ABT-450 and ABT-333. Against that backdrop Roche's Anadys deal at $230M was a smaller, mechanism-focused tuck-in: setrobuvir (non-nuke NS5B) and ANA773 (TLR7) layered onto Roche's interferon franchise (Pegasys/Copegus) and internal DAAs danoprevir and mericitabine. Analysts viewed the 256% premium as defensive — Roche needed combinable assets to protect its dominant interferon revenue stream as the field moved toward all-oral regimens. The strategy ultimately failed: Gilead's sofosbuvir launched in December 2013, and by mid-2015 Roche shelved setrobuvir, marking one of multiple Big Pharma HCV write-downs that decade. (Source: https://www.fiercepharma.com/pharma/anadys-announces-agreement-to-be-acquired-by-roche-0)